Affiliation: Karolinska Institutet
- Characterization of the Alzheimer's disease-associated CLAC protein and identification of an amyloid beta-peptide-binding siteLinda Söderberg
Karolinska Institutet and Sumitomo Pharmaceuticals Alzheimer Center, Neurotec, Novum, SE 141 57 Huddinge, Sweden
J Biol Chem 280:1007-15. 2005..These findings may be useful for future therapeutic interventions aimed at finding compounds that modulate the binding of CLAC to Abeta deposits...
- CLAC binds to aggregated Abeta and Abeta fragments, and attenuates fibril elongationHiroyoshi Kakuyama
Karolinska Institutet and Sumitomo Pharmaceuticals Alzheimer Center KASPAC, Neurotec, Karolinska Institutet, SE 141 57 Huddinge, Sweden
Biochemistry 44:15602-9. 2005..Taken together, we suggest that CLAC becomes involved at an intermediate stage in the pathogenesis by binding to Abeta fibrils, including fibrils formed from peptides with truncated N- or C-termini, and thereby slows their growth...
- Collagenous Alzheimer amyloid plaque component assembles amyloid fibrils into protease resistant aggregatesLinda Söderberg
Karolinska Institutet and Sumitomo Pharmaceuticals Alzheimer Center KASPAC, Neurotec, Novum, Huddinge, Sweden
FEBS J 272:2231-6. 2005..Therefore, CLAC assembles Abeta fibrils into fibril bundles that have an increased resistance to proteases. We suggest that CLAC may act in a similar way in vivo...
- Analysis of single Alzheimer solid plaque cores by laser capture microscopy and nanoelectrospray/tandem mass spectrometryLinda Söderberg
Karolinska Institutet and Dainippon Sumitomo Pharma Alzheimer Center KASPAC, Neurotec, Novum
Biochemistry 45:9849-56. 2006....